Laboratory measurements of the hemophilia B dog G21 after administration of HD vector AdFTC/cFIX/ChMAR
Time, d* . | Alk phos level, U/L . | Bilirubin level, mg/dL . | Amylase, U/L . | PLT count, 103/mm3* . | WBC count, 103/mm3 . | HCT level, % . | HGB, level, g/dL . | CPK level, U/L . | Urea nitrogen level, mg/dL . | Creat level, mg/dL . | Total protein level, g/dL . | Albumin level, g/dL . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −2 | ND | ND | ND | 421 | ND | ND | ND | ND | ND | ND | ND | ND |
| −1 | 94 | 0.1 | 744 | 409 | 14.5 | 41.9 | 14 | 201 | 46 | 0.8 | 5.8 | 3.4 |
| 0 | ND | ND | ND | 399 | 11.2 | 36.9 | 12.2 | ND | ND | ND | ND | ND |
| 0.4 | ND | ND | ND | 322 | 11.4 | 38 | 12.8 | ND | ND | ND | ND | ND |
| 1 | 77 | 0.1 | 721 | ND | ND | ND | ND | 407 | 20 | 0.4 | 5 | 2.9 |
| 2 | 86 | 0.1 | 601 | 394 | 12.8 | 36.5 | 12.3 | 351 | 32 | 1 | 5.4 | 3.2 |
| 3 | 110 | 0.1 | 599 | 364 | 14.1 | 38.9 | 13.2 | 544 | 30 | 0.7 | 5.6 | 3.3 |
| 4 | 91 | 0.1 | 569 | 285 | 10.1 | 32.7 | 11.2L | 447 | 34 | 0.8 | 5.1 | 3.1 |
| 6 | 95 | 0.1 | 640 | 282 | 13.4 | 37.4 | 12.7 | 511 | 46 | 0.8 | 5.4 | 3.2 |
| 7 | 88 | 0.1 | 801 | 221 | 13.1 | 34.2 | 11.8 | 310 | 38 | 0.9 | 4.8 | 3 |
| 8 | 92 | 0.1 | 1000 | 216 | 13.5 | 34.5 | 11.9 | 627 | 28 | 0.8 | 5.3 | 3.2 |
| 10 | 81 | 0.1 | 870 | 234 | 14.7 | 35.3 | 12 | 224 | 47 | 0.9 | 5.3 | 3.1 |
Time, d* . | Alk phos level, U/L . | Bilirubin level, mg/dL . | Amylase, U/L . | PLT count, 103/mm3* . | WBC count, 103/mm3 . | HCT level, % . | HGB, level, g/dL . | CPK level, U/L . | Urea nitrogen level, mg/dL . | Creat level, mg/dL . | Total protein level, g/dL . | Albumin level, g/dL . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −2 | ND | ND | ND | 421 | ND | ND | ND | ND | ND | ND | ND | ND |
| −1 | 94 | 0.1 | 744 | 409 | 14.5 | 41.9 | 14 | 201 | 46 | 0.8 | 5.8 | 3.4 |
| 0 | ND | ND | ND | 399 | 11.2 | 36.9 | 12.2 | ND | ND | ND | ND | ND |
| 0.4 | ND | ND | ND | 322 | 11.4 | 38 | 12.8 | ND | ND | ND | ND | ND |
| 1 | 77 | 0.1 | 721 | ND | ND | ND | ND | 407 | 20 | 0.4 | 5 | 2.9 |
| 2 | 86 | 0.1 | 601 | 394 | 12.8 | 36.5 | 12.3 | 351 | 32 | 1 | 5.4 | 3.2 |
| 3 | 110 | 0.1 | 599 | 364 | 14.1 | 38.9 | 13.2 | 544 | 30 | 0.7 | 5.6 | 3.3 |
| 4 | 91 | 0.1 | 569 | 285 | 10.1 | 32.7 | 11.2L | 447 | 34 | 0.8 | 5.1 | 3.1 |
| 6 | 95 | 0.1 | 640 | 282 | 13.4 | 37.4 | 12.7 | 511 | 46 | 0.8 | 5.4 | 3.2 |
| 7 | 88 | 0.1 | 801 | 221 | 13.1 | 34.2 | 11.8 | 310 | 38 | 0.9 | 4.8 | 3 |
| 8 | 92 | 0.1 | 1000 | 216 | 13.5 | 34.5 | 11.9 | 627 | 28 | 0.8 | 5.3 | 3.2 |
| 10 | 81 | 0.1 | 870 | 234 | 14.7 | 35.3 | 12 | 224 | 47 | 0.9 | 5.3 | 3.1 |
Hemophilia dog G21 received 6.0 × 1011 vp/kg body weight of the HD vector AdFTC/cFIX/ChMAR. Samples were collected periodically and the samples on day 0 and before were obtained prior to any treatment. Abbreviations are explained in Table 2.
Most significant measurements.